Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus
Groups of mice infected with 3.3 × 108 Stapyhlococcus aureus via the tail vein were treated three days later with rifampicin (13 mg/kg), vancomycin (33 mg/kg), or teicoplanin (33 mg/kg). Rifampicin was the most effective agent (28 out of 29 survivors). Vancomycin and teicoplanin were of equivalent e...
Gespeichert in:
Veröffentlicht in: | Journal of antimicrobial chemotherapy 1987-05, Vol.19 (5), p.659-662 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 662 |
---|---|
container_issue | 5 |
container_start_page | 659 |
container_title | Journal of antimicrobial chemotherapy |
container_volume | 19 |
creator | Carper, Holliday T. Sullivan, Gail W. Mandell, Gerald L. |
description | Groups of mice infected with 3.3 × 108 Stapyhlococcus aureus via the tail vein were treated three days later with rifampicin (13 mg/kg), vancomycin (33 mg/kg), or teicoplanin (33 mg/kg). Rifampicin was the most effective agent (28 out of 29 survivors). Vancomycin and teicoplanin were of equivalent efficacy (21 of 29 and 24 of 29 survivors, respectively). When intraleucocytic staphylococci were incubated with rifampicin (1 or 20 mg/l), vancomycin (100 mg/l), or teicoplanin (100 mg/l), rifampicin was the most active drug. Vancomycin and teicoplanin were similar. |
doi_str_mv | 10.1093/jac/19.5.659 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77613413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77613413</sourcerecordid><originalsourceid>FETCH-LOGICAL-c268t-75a5e5875f1974974ab00d4af201666bae3c46b90fb8aed9d44fe8d0879ff9033</originalsourceid><addsrcrecordid>eNo9kF2L1DAUhoMo67h6563QC_FqO3vSNEnjnawfK-yq6IqLCOE0TdisbVOTdnT-vRlmGDhwXngfDpyHkOcU1hQUO79Hc07Vmq8FVw_IitYCygoUfUhWwICXsubsMXmS0j0ACC6aE3JSKS6qSq3IrxvrTZh6HP14VmxwNGHYml2O3uEw-ZxfF34sN34TChy7fZ5jKNK8dN6m4q-f74pvM0532z6YYMySClyiXdJT8shhn-yzwz4l39-_u7m4LK8-f_h48eaqNJVo5lJy5JY3kjuqZJ0HW4CuRlcBFUK0aJmpRavAtQ3aTnV17WzTQSOVcwoYOyWv9nenGP4sNs168MnYPn9lw5K0lIKymu7Asz1oYkgpWqen6AeMW01B72TqLFNTpbnOMjP-4nB3aQfbHeGDvdy_PPSYDPYuZn0-HbGmolwKyFi5x3ya7b9jjfG3FpJJri9vf-rrH7dfPr2Fa_2V_Qdv0o0R</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77613413</pqid></control><display><type>article</type><title>Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus</title><source>Oxford University Press Journals Digital Archive legacy</source><source>MEDLINE</source><creator>Carper, Holliday T. ; Sullivan, Gail W. ; Mandell, Gerald L.</creator><creatorcontrib>Carper, Holliday T. ; Sullivan, Gail W. ; Mandell, Gerald L.</creatorcontrib><description>Groups of mice infected with 3.3 × 108 Stapyhlococcus aureus via the tail vein were treated three days later with rifampicin (13 mg/kg), vancomycin (33 mg/kg), or teicoplanin (33 mg/kg). Rifampicin was the most effective agent (28 out of 29 survivors). Vancomycin and teicoplanin were of equivalent efficacy (21 of 29 and 24 of 29 survivors, respectively). When intraleucocytic staphylococci were incubated with rifampicin (1 or 20 mg/l), vancomycin (100 mg/l), or teicoplanin (100 mg/l), rifampicin was the most active drug. Vancomycin and teicoplanin were similar.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/19.5.659</identifier><identifier>PMID: 2956229</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Animals ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Glycopeptides - pharmacology ; Glycopeptides - therapeutic use ; Male ; Medical sciences ; Mice ; Mice, Inbred ICR ; Microbial Sensitivity Tests ; Pharmacology. Drug treatments ; Random Allocation ; Rifampin - pharmacology ; Rifampin - therapeutic use ; Staphylococcal Infections - drug therapy ; Staphylococcus aureus - drug effects ; Teicoplanin ; Vancomycin - pharmacology ; Vancomycin - therapeutic use</subject><ispartof>Journal of antimicrobial chemotherapy, 1987-05, Vol.19 (5), p.659-662</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c268t-75a5e5875f1974974ab00d4af201666bae3c46b90fb8aed9d44fe8d0879ff9033</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8215760$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2956229$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carper, Holliday T.</creatorcontrib><creatorcontrib>Sullivan, Gail W.</creatorcontrib><creatorcontrib>Mandell, Gerald L.</creatorcontrib><title>Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Groups of mice infected with 3.3 × 108 Stapyhlococcus aureus via the tail vein were treated three days later with rifampicin (13 mg/kg), vancomycin (33 mg/kg), or teicoplanin (33 mg/kg). Rifampicin was the most effective agent (28 out of 29 survivors). Vancomycin and teicoplanin were of equivalent efficacy (21 of 29 and 24 of 29 survivors, respectively). When intraleucocytic staphylococci were incubated with rifampicin (1 or 20 mg/l), vancomycin (100 mg/l), or teicoplanin (100 mg/l), rifampicin was the most active drug. Vancomycin and teicoplanin were similar.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Glycopeptides - pharmacology</subject><subject>Glycopeptides - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred ICR</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Random Allocation</subject><subject>Rifampin - pharmacology</subject><subject>Rifampin - therapeutic use</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Teicoplanin</subject><subject>Vancomycin - pharmacology</subject><subject>Vancomycin - therapeutic use</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kF2L1DAUhoMo67h6563QC_FqO3vSNEnjnawfK-yq6IqLCOE0TdisbVOTdnT-vRlmGDhwXngfDpyHkOcU1hQUO79Hc07Vmq8FVw_IitYCygoUfUhWwICXsubsMXmS0j0ACC6aE3JSKS6qSq3IrxvrTZh6HP14VmxwNGHYml2O3uEw-ZxfF34sN34TChy7fZ5jKNK8dN6m4q-f74pvM0532z6YYMySClyiXdJT8shhn-yzwz4l39-_u7m4LK8-f_h48eaqNJVo5lJy5JY3kjuqZJ0HW4CuRlcBFUK0aJmpRavAtQ3aTnV17WzTQSOVcwoYOyWv9nenGP4sNs168MnYPn9lw5K0lIKymu7Asz1oYkgpWqen6AeMW01B72TqLFNTpbnOMjP-4nB3aQfbHeGDvdy_PPSYDPYuZn0-HbGmolwKyFi5x3ya7b9jjfG3FpJJri9vf-rrH7dfPr2Fa_2V_Qdv0o0R</recordid><startdate>198705</startdate><enddate>198705</enddate><creator>Carper, Holliday T.</creator><creator>Sullivan, Gail W.</creator><creator>Mandell, Gerald L.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198705</creationdate><title>Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus</title><author>Carper, Holliday T. ; Sullivan, Gail W. ; Mandell, Gerald L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c268t-75a5e5875f1974974ab00d4af201666bae3c46b90fb8aed9d44fe8d0879ff9033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Glycopeptides - pharmacology</topic><topic>Glycopeptides - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred ICR</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Random Allocation</topic><topic>Rifampin - pharmacology</topic><topic>Rifampin - therapeutic use</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Teicoplanin</topic><topic>Vancomycin - pharmacology</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carper, Holliday T.</creatorcontrib><creatorcontrib>Sullivan, Gail W.</creatorcontrib><creatorcontrib>Mandell, Gerald L.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carper, Holliday T.</au><au>Sullivan, Gail W.</au><au>Mandell, Gerald L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1987-05</date><risdate>1987</risdate><volume>19</volume><issue>5</issue><spage>659</spage><epage>662</epage><pages>659-662</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Groups of mice infected with 3.3 × 108 Stapyhlococcus aureus via the tail vein were treated three days later with rifampicin (13 mg/kg), vancomycin (33 mg/kg), or teicoplanin (33 mg/kg). Rifampicin was the most effective agent (28 out of 29 survivors). Vancomycin and teicoplanin were of equivalent efficacy (21 of 29 and 24 of 29 survivors, respectively). When intraleucocytic staphylococci were incubated with rifampicin (1 or 20 mg/l), vancomycin (100 mg/l), or teicoplanin (100 mg/l), rifampicin was the most active drug. Vancomycin and teicoplanin were similar.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>2956229</pmid><doi>10.1093/jac/19.5.659</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0305-7453 |
ispartof | Journal of antimicrobial chemotherapy, 1987-05, Vol.19 (5), p.659-662 |
issn | 0305-7453 1460-2091 |
language | eng |
recordid | cdi_proquest_miscellaneous_77613413 |
source | Oxford University Press Journals Digital Archive legacy; MEDLINE |
subjects | Animals Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Glycopeptides - pharmacology Glycopeptides - therapeutic use Male Medical sciences Mice Mice, Inbred ICR Microbial Sensitivity Tests Pharmacology. Drug treatments Random Allocation Rifampin - pharmacology Rifampin - therapeutic use Staphylococcal Infections - drug therapy Staphylococcus aureus - drug effects Teicoplanin Vancomycin - pharmacology Vancomycin - therapeutic use |
title | Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A05%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Teicoplanin,%20vancomycin,%20rifampicin:%20in-vivo%20and%20in-vitro%20studies%20with%20Staphylococcus%20aureus&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Carper,%20Holliday%20T.&rft.date=1987-05&rft.volume=19&rft.issue=5&rft.spage=659&rft.epage=662&rft.pages=659-662&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/19.5.659&rft_dat=%3Cproquest_cross%3E77613413%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77613413&rft_id=info:pmid/2956229&rfr_iscdi=true |